Hypophysitis induced by immune checkpoint inhibitors in a Scottish melanoma population.

IF 1 Q4 ONCOLOGY Melanoma Management Pub Date : 2019-04-15 eCollection Date: 2019-03-01 DOI:10.2217/mmt-2018-0009

Khor Zhong Wei, Mark Baxter, Richard Casasola

引用次数: 14

Abstract

Aim: This study aims to determine the incidence of all immune-mediated adverse events (IMAEs) with a focus on hypophysitis in patients with metastatic melanoma receiving immune checkpoint inhibitors (ICI).

Methods: 51 patients with metastatic melanoma who received immune checkpoint inhibitors (ipilimumab, pembrolizumab and nivolumab) in Ninewells Hospital, Dundee between 2014 and 2018 were identified. Patient demographic data and outcomes were recorded retrospectively.

Results: A total of 6 patients (11.7%) developed hypophysitis, while 15 patients (29.4%) developed IMAEs. A significant improvement in overall survival (p = 0.03) and progression-free survival (p = 0.041) was seen in patients who developed IMAEs compared with those who did not.

Conclusion: This study demonstrates a high rate of hypophysitis in melanoma patients receiving ipilimumab. Careful monitoring of symptoms is crucial to detect and appropriately manage IMAEs.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

苏格兰黑色素瘤人群中免疫检查点抑制剂诱导的垂体炎。

目的:本研究旨在确定所有免疫介导的不良事件(imae)的发生率，重点关注接受免疫检查点抑制剂(ICI)治疗的转移性黑色素瘤患者的垂体炎。方法:选取2014年至2018年在邓迪Ninewells医院接受免疫检查点抑制剂(ipilimumab、pembrolizumab和nivolumab)治疗的51例转移性黑色素瘤患者。回顾性记录患者人口统计资料和结果。结果:6例(11.7%)发生垂体炎，15例(29.4%)发生imae。与未发生imae的患者相比，发生imae的患者的总生存期(p = 0.03)和无进展生存期(p = 0.041)有显著改善。结论:本研究表明，接受伊匹单抗治疗的黑色素瘤患者发生垂体炎的几率很高。仔细监测症状对于发现和适当管理imae至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Melanoma Management ONCOLOGY-

CiteScore

5.10

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Skin cancer is on the rise. According to the World Health Organization, 132,000 melanoma skin cancers occur globally each year. While early-stage melanoma is usually relatively easy to treat, once disease spreads prognosis worsens considerably. Therefore, research into combating advanced-stage melanoma is a high priority. New and emerging therapies, such as monoclonal antibodies, B-RAF and KIT inhibitors, antiangiogenic agents and novel chemotherapy approaches hold promise for prolonging survival, but the search for a cure is ongoing. Melanoma Management publishes high-quality peer-reviewed articles on all aspects of melanoma, from prevention to diagnosis and from treatment of early-stage disease to late-stage melanoma and metastasis. The journal presents the latest research findings in melanoma research and treatment, together with authoritative reviews, cutting-edge editorials and perspectives that highlight hot topics and controversy in the field. Independent drug evaluations assess newly approved medications and their role in clinical practice. Key topics covered include: Risk factors, prevention and sun safety education Diagnosis, staging and grading Surgical excision of melanoma lesions Sentinel lymph node biopsy Biological therapies, including immunotherapy and vaccination Novel chemotherapy options Treatment of metastasis Prevention of recurrence Patient care and quality of life.